Literature DB >> 23019056

A long-term outcome of therapeutic angiogenesis by transplantation of peripheral blood stem cells in critical limb ischemia after interventional revascularization.

Alavala Matta Reddy1, Byung Kook Kwak, Hyung Jin Shim, Eui-Chan Jang, Ae Ja Park, Eunkyung Park, Chiyoung Ahn.   

Abstract

A 61-year-old male patient with atherosclerotic critical limb ischemia in the left leg underwent stent insertion into the left superficial femoral artery. Stenting procedures improved Rutherford grade from III-5 to II-4. Granulocyte colony-stimulating factor stimulated the production of white blood cells over four-fold and mononuclear cells (MNCs) 1.5-fold in the whole blood. Transplantation of 7.9x10(9) autologous MNCs into the left femoral artery rapidly decreased the leg pain intensity, with further improvement of Rutherford grades from II-4 to 0-0 without any side effects. In the four-year follow-up, significant improvement was found in terms of ankle brachial index, from nondetectable to 0.67, and peak systolic velocity, from 14.8 to 36.1 cm/s. Limb salvage and decreased resting pain were the notable outcomes of the treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23019056     DOI: 10.4261/1305-3825.DIR.5877-12.2

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  2 in total

1.  Autologous transplantation of CD34(+) bone marrow derived mononuclear cells in management of non-reconstructable critical lower limb ischemia.

Authors:  Ahmed M Ismail; Said M Abdou; Hassan Abdel Aty; Adel H Kamhawy; Mohammed Elhinedy; Mohammed Elwageh; Atef Taha; Amal Ezzat; Hoda A Salem; Said Youssif; Mohamed L Salem
Journal:  Cytotechnology       Date:  2014-12-16       Impact factor: 2.058

2.  Long-Term Outcomes of BMMSC Compared with BMMNC for Treatment of Critical Limb Ischemia and Foot Ulcer in Patients with Diabetes.

Authors:  Debin Lu; Youzhao Jiang; Wuquan Deng; Yan Zhang; Ziwen Liang; Qinan Wu; Xiaoyan Jiang; Ling Zhang; Fang Gao; Ying Cao; Bing Chen; Yaoming Xue
Journal:  Cell Transplant       Date:  2019-03-27       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.